Clinical and immunomodulatory effects of bevacizumab and low-dose interleukin-2 in patients with metastatic renal cell carcinoma: results from a phase II trial-Reference-Cited by-同舟云学术

Clinical and immunomodulatory effects of bevacizumab and low-dose interleukin-2 in patients with metastatic renal cell carcinoma: results from a phase II trial

Published:2010-09-14 Issue:4 Volume:107 Page:562-570
ISSN:1464-4096
Container-title:BJU International
language:en
Short-container-title:

Author:

Garcia Jorge A.,Mekhail Tarek,Elson Paul,Triozzi Pierre,Nemec Cheryl,Dreicer Robert,Bukowski Ronald M.,Rini Brian I

Publisher

Wiley

Subject

Urology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/j.1464-410X.2010.09573.x/fullpdf

Reference44 articles.

1. Interferon-alpha and survival in metastatic renal carcinoma: early results of a randomised controlled trial;Medical Research Council Renal Cancer Collaborators;Lancet,1999

2. Prospective randomized trial of interferon alfa-2a plus vinblastine versus vinblastine alone in patients with advanced renal cell cancer;Pyrhönen;J Clin Oncol,1999

3. Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma;Motzer;J Clin Oncol,2002

4. Recombinant human interleukin-2, recombinant human interferon alfa-2a, or both in metastatic renal-cell carcinoma. Groupe Francais d’Immunotherapie;Negrier;N Engl J Med,1998

5. Immunotherapy for advanced renal cell cancer;Coppin;Cochrane Database Syst Rev,2005

Cited by 18 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Remodeling the immune microenvironment for gastric cancer therapy through antagonism of prostaglandin E2 receptor 4;Genes & Diseases;2023-11

2. A homodimeric IL-15 superagonist F4RLI with easy preparation, improved half-life, and potent antitumor activities;Applied Microbiology and Biotechnology;2022-10-03

3. Development of a Phagocytosis-Dependent Gene Signature to Predict Prognosis and Response to Checkpoint Inhibition in Clear-Cell Renal Cell Carcinoma;Frontiers in Immunology;2022-05-16

4. Combination of Anti-Angiogenics and Checkpoint Inhibitors for Renal Cell Carcinoma: Is the Whole Greater Than the Sum of Its Parts?;Cancers;2022-01-27

5. CD303 (BDCA-2) – a potential novel target for therapy in hematologic malignancies;Leukemia & Lymphoma;2021-09-06